Pivotal Life Sciences overview
Stories about Pivotal Life Sciences
Pivotal China wraps up initial fund at $150 mln
Pivotal China has closed its inaugural fund at $150 million. Pivotal bioVenture Partners China USD Fund I will focus on incubating and building life sciences companies in China.
Oculis nabs $20.3 mln Series B
Oculis, a Swiss developer of ophthalmic drugs, has raised $20.3 million in Series B funding. The investors included Bay City Capital, Novartis Venture Fund, Pivotal bioVenture Partners, Brunnur Ventures and Silfurberg.
SutroVax rakes in $60 mln Series B
Foster City, California-based SutroVax, a biopharmaceutical vaccine company, has secured $60 million Series B financing. Frazier Healthcare Partners and Pivotal bioVenture Partners led the round with participation from other backers that included Abingworth, Longitude Capital, Roche Venture Fund and CTI Life Sciences Fund. In addition to the funding, Patrick Heron and Tracy Saxton have been appointed to SutroVax's board of directors.
Pivotal Life Sciences contact information
Offices
501 2nd Street, Suite 200, San Francisco, 94107, United StatesContacts
| Name | Job title | Location | |
|---|---|---|---|
Key Contact Mr. Meng Gao | Job titleGroup Chief Investment Officer | LocationHong Kong, Hong Kong | Email  ----------- |
| Ms. Shiva Amiri | Job titlePartner & Chief Data Science Officer | LocationSan Francisco, United States | Email ------ |
| Ms. Anna Sun | Job titleChief Operating Officer, China | LocationHong Kong, Hong Kong | Email ---------- |
| Ms. Mischa Travers | Job titleChief Operating Officer and General Counsel, US | LocationSan Francisco, United States | Email ----- |
Pivotal Life Sciences funds managed
Closed funds: 5
| Fund | Fund size | Close date | Strategy |
|---|---|---|---|
Fund size ----------- | Close dateDec 2023 | Strategy -------- | |
Fund size ---------- | Close dateMar 2018 | Strategy ------- | |
Fund size ----- | Close dateMar 2017 | Strategy ----- | |
Stories that mention Pivotal Life Sciences
DermBiont lands $28m Series A2
DermBiont, a developer of targeted topical therapeutics that address the root causes of skin diseases, has raised $28 million in Series A2 financing.
Evommune pulls in $83m Series A
Evommune, Inc., a private R&D company and innovation engine in chronic inflammation, has secured $83 million in Series A financing.
Fusion Pharmaceuticals goes public, expects to raise $212m
Fusion Pharmaceuticals, a Hamilton, Ontario-based cancer radiotherapeutics company, has priced its IPO on the NASDAQ at US$17 per share.
VC-backed Fusion Pharmaceuticals seeks $125m from IPO: report
Canadian cancer radiotherapeutics specialist Fusion Pharmaceuticals is looking to raise US$125 million (C$170 million) from its initial public offering on Nasdaq.
Rallybio inks $145m Series B
New Haven, Connecticut-based Rallybio, a biopharmaceutical company, has closed $145 million in Series B funding.
VC-backed Karuna goes public
Karuna Therapeutics, a biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions, has raised $89.2 million for its IPO after pricing its over 5.5 million shares at $16 per share. The stock began trading June 28, 2019 on the NASDAQ under the ticker symbol "KRTX." Goldman Sachs and Citigroup are the lead underwriters. Karuna's pre-IPO backers included ARCH Venture Partners, Fidelity Management & Research Co, Eventide Asset Management, Pivotal bioVenture Partners, Partner Fund Management, Wellcome Trust, Sands Capital and Alexandria Venture Investments.
Canadian VC begins 2019 with heft as top Q1 deals raise $667 mln
After nine straight years of growth, Canada’s venture capital market showed no signs of slowing down in early 2019. The top 10 first-quarter VC financings drew $667 million from VC funds. While that’s down 28 percent from the $923 million raised by the top 10 deals a year earlier, it exceeds first-quarter results in other recent years. The estimate is based on PE Hub Canada’s list of the largest rounds announced from January through March, supplemented by preliminary data from Refinitiv. It suggests that despite increasing market uncertainty, trends in early 2019 reflect many of the same factors that drove soaring Canadian VC investment activity last year.